Table 1: The anti-CA III, IV titers, and the CA activity of subjects (mean (SD)).

RASLET1DT1DNT2DT2DNHTNHT

anti-CA III (abs)control0.058 (0.015)0.056 (0.021)0.064 (0.015)0.041 (0.009)0.053 (0.012)0.064 (0.013)0.049 (0.010)0.061 (0.012)
patients 0.195* (0.079)0.327* (0.644)0.073 (0.022)0.204* (0.083)0.065 (0.023)0.056 (0.019)0.096 (0.057)0.065 (0.025)
positive11.2%14.8%0.0%6.7%0.0%0.0%0.0%0.0%

anti-CA IV (abs)control0.021 (0.013)0.032 (0.013)0.027 (0.006)0.019 (0.007)0.026 (0.009)0.027 (0.011)0.035 (0.012)0.026 (0.009)
patients 0.183* (0.063)0.205* (0.688)0.033 (0.013)0.022* (0.105)0.022 (0.006)0.049 (0.018)0.028 (0.011)0.131* (0.045)
positive9.8%10.6%0.0%4.2%0.0%0.0%0.0%5.3%

CA activity (EU/mL)control8.65 (2.86)7.96 (3.12)8.12 (2.57)8.56 (2.13)8.63 (2.64)8.47 (2.32)7.98 (3.65)8.12 (2.43)
patients 10.37* (4.36)12.48* (5.68)8.66
(4.36)
13.07* (5.58)9.32
(3.97)
12.65* (4.56)9.65* (4.51)13.47* (5.08)

*There were significant differences between patients and control (P < 0.05).
n = 10 (5 males and 5 females).
HTN: hypertensive nephropathy; HT: heart failure.